AVIR

Atea Pharmaceuticals (AVIR)

Atea Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:AVIR

1 2 3 4 5 6 7 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/15	05 : 43	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2024/05/15	05 : 16	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2024/05/15	05 : 05	GlobeNewswire Inc.	Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2024/05/07	20 : 00	GlobeNewswire Inc.	Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2024/04/29	20 : 00	GlobeNewswire Inc.	Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2024/03/27	20 : 00	GlobeNewswire Inc.	Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2024/02/29	06 : 18	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2024/02/29	06 : 05	GlobeNewswire Inc.	Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2024/02/21	21 : 00	GlobeNewswire Inc.	Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2024/02/03	11 : 29	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2024/02/03	11 : 26	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2024/02/03	11 : 25	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2024/02/03	11 : 24	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2024/02/02	06 : 15	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2024/02/02	06 : 15	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2024/02/02	06 : 15	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2024/02/02	06 : 15	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2024/01/09	06 : 05	GlobeNewswire Inc.	Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2024/01/03	21 : 00	GlobeNewswire Inc.	Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2023/11/13	21 : 00	GlobeNewswire Inc.	Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2023/11/09	06 : 43	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2023/11/09	06 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2023/11/09	06 : 05	GlobeNewswire Inc.	Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2023/11/08	21 : 00	GlobeNewswire Inc.	Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2023/11/02	20 : 00	GlobeNewswire Inc.	Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2023/11/01	20 : 00	GlobeNewswire Inc.	Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2023/09/06	20 : 00	GlobeNewswire Inc.	Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2023/08/09	05 : 46	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2023/08/09	05 : 21	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AVIR	Atea Pharmaceuticals Inc
2023/08/09	05 : 05	GlobeNewswire Inc.	Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update	NASDAQ:AVIR	Atea Pharmaceuticals Inc